HR 2503

FDA Scientific Fairness for Women Act

Congress: 110 (2007–2009, Ended)
Chamber: House
Policy Area: Health
Introduced: May 24, 2007
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (May 24, 2007)
Official Text: https://www.congress.gov/bill/110th-congress/house-bill/2503

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]
Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (21 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Farr, Sam [D-CA-17]	D · CA		May 24, 2007
Rep. Grijalva, Raúl M. [D-AZ-7]	D · AZ		May 24, 2007
Rep. Napolitano, Grace F. [D-CA-38]	D · CA		May 24, 2007
Rep. Rush, Bobby L. [D-IL-1]	D · IL		May 24, 2007
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		May 24, 2007
Rep. Solis, Hilda L. [D-CA-32]	D · CA		May 24, 2007
Rep. Sutton, Betty [D-OH-13]	D · OH		May 24, 2007
Rep. Wexler, Robert [D-FL-19]	D · FL		May 24, 2007
Rep. Woolsey, Lynn C. [D-CA-6]	D · CA		May 24, 2007
Rep. Baldwin, Tammy [D-WI-2]	D · WI		Jun 11, 2007
Rep. Davis, Susan A. [D-CA-53]	D · CA		Jun 11, 2007
Rep. Kilpatrick, Carolyn C. [D-MI-13]	D · MI		Jun 11, 2007
Rep. Capps, Lois [D-CA-23]	D · CA		Jun 26, 2007
Rep. Holt, Rush [D-NJ-12]	D · NJ		Sep 4, 2007
Rep. Wynn, Albert Russell [D-MD-4]	D · MD		Sep 7, 2007
Rep. Engel, Eliot L. [D-NY-17]	D · NY		Sep 18, 2007
Rep. Abercrombie, Neil [D-HI-1]	D · HI		Sep 24, 2007
Rep. Boucher, Rick [D-VA-9]	D · VA		Sep 24, 2007
Rep. Rothman, Steven R. [D-NJ-9]	D · NJ		Sep 24, 2007
Rep. Sestak, Joe [D-PA-7]	D · PA		Oct 17, 2007
Rep. DeGette, Diana [D-CO-1]	D · CO		Feb 13, 2008

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 24, 2007

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of May 24, 2007)

FDA Scientific Fairness for Women Act - Amends the Federal Food, Drug, and Cosmetic Act to establish the Office of Women's Health within the Office of the Commissioner of the Food and Drug Administration (FDA).

Deems a breast implant to be a class III medical device. Requires premarket approval of breast implants irrespective of whether the implant has been cleared for commercial distribution in interstate commerce before the date of enactment of this Act.

Prohibits the Secretary of Health and Human Services from finding that a reasonable assurance of safety has been shown for an application for premarket approval for a a breast implant unless the applicant involved has demonstrated its safety for the life of the implant. Deems an already approved breast implant to be unsafe under the conditions of use prescribed, recommended, or suggested in the labeling.

Requires the Secretary to: (1) issue appropriate, voluntary guidance for clinical care, removal, and replacement for breast implants; (2) require such guidance to be clearly expressed in the labeling and all marketing materials; and (3) require dissemination of such guidance to patients who have already received the implant.

Requires the Breast Implant Advisory Panel of the General and Plastic Surgery Advisory Committee to review the results and quality of the research on saline breast implants and silicone gel implants.

Requires the Secretary to study the ionization and levels of platinum in silicone breast implants.

Requires the Secretary, acting through the Commissioner of Food and Drugs, to convene a scientific workshop to review and evaluate current scientific data on the use of emergency contraception by females of childbearing potential under the age of 18.

Actions Timeline

- **May 24, 2007:** Introduced in House
- **May 24, 2007:** Referred to the House Committee on Energy and Commerce.
- **May 24, 2007:** Referred to the Subcommittee on Health.

Generated by **LegiList** — https://legilist.com · Public data belongs to the public.